人口学、医疗可及性、治疗与肿瘤特征对晚期前列腺癌生存种族差异的贡献评估
该研究利用美国国家癌症数据库2004–2010年35,611例晚期前列腺癌男性(黑人5,927例,16.77%),通过序贯倾向评分加权模拟人口学、医疗可及性、治疗和肿瘤特征相等的队列。校正人口学与合并症后黑人死亡风险更高(HR 1.27,95%CI 1.2–1.34,P<0.001);模拟医疗可及性相等后种族差异无统计学意义(HR 1.04,95%CI 0.97–1.12,P=0.276);医疗可及性相关变量解释了黑人超额死亡风险的84.7%。
要点
- 校正人口学与合并症后黑人晚期前列腺癌总生存更差(HR 1.27)。
- 模拟医疗可及性相等后种族生存差异无统计学意义(HR 1.04)。
- 医疗可及性相关变量解释黑人超额死亡风险的84.7%。
核心结论
- 晚期前列腺癌黑人总生存更差,但校正医疗可及性、治疗和肿瘤特征后黑人种族与更好总生存相关。
- 改善医疗可及性可能是缩小前列腺癌结局种族差异的有效工具。
研究设计与样本
- 基于美国国家癌症数据库2004–2010年≥40岁转移性或局部晚期前列腺癌(cN+ cM+和/或T3/4)男性,共35,611例,其中黑人5,927例(16.77%)。
- 采用序贯倾向评分加权生成人口学、医疗可及性、治疗和肿瘤特征相等的模拟队列,并以校正生存分析比较。
主要发现
- 校正人口学与合并症后黑人死亡风险显著更高(HR 1.27,95%CI 1.2–1.34,P<0.001)。
- 模拟医疗可及性相等后种族生存差异无统计学意义(HR 1.04,95%CI 0.97–1.12,P=0.276)。
- 模拟治疗相等后黑人总生存优于白人,但差异无统计学意义(HR 0.93,95%CI 0.86–1.01,P=0.071)。
- 模拟肿瘤特征相等后黑人总生存显著优于白人(HR 0.92,95%CI 0.84–1.00,P=0.043)。
- 医疗可及性相关变量解释了黑人超额死亡风险的84.7%。
临床怎么用
- 晚期前列腺癌诊疗中应关注医疗可及性因素对生存差异的影响。
- 改善医疗可及性可作为缩小前列腺癌结局种族差异的干预方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Racial differences in prostate cancer (PCa) outcomes in the United States may be due to differences in tumor biology and race-based differences in access and treatment. We designed a study to estimate the relative contribution of these factors on Black/White disparities in overall survival (OS) in advanced PCa. METHODS: We identified Black and White men aged ≥ 40 years with metastatic or locally advanced PCa (cN+ cM+ and/or T3/4) between 2004 and 2010 using the National Cancer Database. We employed sequential propensity score weighting procedures to generate simulated cohorts of Black and White patients with equal demographics, access to care, treatment, and tumor characteristics. Adjusted survival analyses were used to compare survival in these simulated cohorts. The changes in relative survival after each weighting procedure were used to infer the contribution of each set of variables on the excess risk of mortality in Blacks. RESULTS: In total, 35,611 men met inclusion criteria, 5927 (16.77%) of whom were Black. Survival was significantly worse for Black men after adjusting for demographics and comorbidities (hazard ratio (HR) 1.27, 95%-confidence interval (95%-CI) 1.2-1.34, p < 0.001). After simulating equal access to care, there was no significant difference in survival between races (HR 1.04, 95%-CI 0.97-1.12, p = 0.276), despite worse tumor characteristics in Blacks. After simulating equal treatment and equivalent tumor characteristics, Black men had a better survival than Whites (HR 0.93, 95%-CI 0.86-1.01, p = 0.071 and HR 0.92, 95%-CI 0.84-1.00, p = 0.043, respectively). Overall, access-related variables explained 84.7% of the excess risk of death in Black men. CONCLUSION: Our analysis of men with advanced PCa revealed worse OS among Blacks. However, when access to care, treatment, and cancer characteristics are accounted for, Black race was associated with better OS. These findings suggest that initiatives to improve access to care may represent an effective tool to reduce disparities in PCa outcomes.
引用
- Krimphove MJ, Cole AP, Fletcher SA, et al. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 30171227. doi:10.1038/s41391-018-0083-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。